Quarterly report · Q3

Period2023-01-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥119m2023-01-01 → 2023-09-30StandaloneNet sales
Revenue¥126m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥88m2022-01-01 → 2022-09-30StandaloneNet sales
Operating income−¥577m2023-01-01 → 2023-09-30StandaloneOperating income
Operating income−¥564m2022-01-01 → 2022-09-30StandaloneOperating income
Ordinary income−¥587m2023-01-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥754m2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥571m2022-01-01 → 2022-09-30StandaloneOrdinary income
Profit before tax−¥584m2023-01-01 → 2023-09-30StandaloneIncome before income taxes
Profit before tax−¥572m2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Net income−¥585m2023-01-01 → 2023-09-30StandaloneProfit loss
Net income−¥760m2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥574m2022-01-01 → 2022-09-30StandaloneProfit loss
Total assets¥2.6bnat 2023-09-30StandaloneAssets
Total assets¥1.5bnat 2022-12-31StandaloneAssets
Total assets¥1.5bnat 2022-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥390mat 2023-09-30StandaloneLiabilities
Total liabilities¥366mat 2022-12-31StandaloneLiabilities
Net assets / equity¥2.3bnat 2023-09-30StandaloneNet assets
Net assets / equity¥1.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2022-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥2.2bnat 2023-09-30StandaloneCash and deposits
Cash and deposits¥1.1bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-20.952023-01-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-7.622023-07-01 → 2023-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.312022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.382022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-9.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio84.4%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio74.8%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio71.3%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued30,889,419at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued24,422,619at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued22,159,419at 2022-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥147m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2023-01-01 → 2023-09-30¥8m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2023-01-01 → 2023-09-30¥8m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2023-01-01 → 2023-09-30−¥394m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2023-01-01 → 2023-09-30¥111m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2023-01-01 → 2023-09-30¥111m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2023-01-01 → 2023-09-30−¥36m
—segment totalrevenue2023-01-01 → 2023-09-30¥119m
—segment totalrevenue external2023-01-01 → 2023-09-30¥119m
—segment totalsegment profit2023-01-01 → 2023-09-30−¥430m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥147m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue2022-01-01 → 2022-09-30¥7m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentrevenue external2022-01-01 → 2022-09-30¥7m
jpcrp040300-q3r_E24158-000Cell Sheet Regenerative Medicinereportable segmentsegment profit2022-01-01 → 2022-09-30−¥347m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue2022-01-01 → 2022-09-30¥81m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentrevenue external2022-01-01 → 2022-09-30¥81m
jpcrp040300-q3r_E24158-000Laboratory Consumable Equipmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥70m
—segment totalrevenue2022-01-01 → 2022-09-30¥88m
—segment totalrevenue external2022-01-01 → 2022-09-30¥88m
—segment totalsegment profit2022-01-01 → 2022-09-30−¥418m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 307
ItemContextValueUnit
Independent auditors report non consolidated (text)FilingDateInstantText · Plus
Audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)けやき監査法人
Cpa1 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)吉 村  潤 一
Cpa2 audit firm1 non consolidatedFilingDateInstant
Original text (Japanese)宮 下  圭 二
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration_NonConsolidatedMember88185000JPY
Net sales (5-year summary)CurrentYTDDuration_NonConsolidatedMember119202000JPY
Net sales (5-year summary)Prior1YearDuration_NonConsolidatedMember126427000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration_NonConsolidatedMember-570781000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration_NonConsolidatedMember-586995000JPY
Ordinary income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-754274000JPY
Net income loss (5-year summary)Prior1YTDDuration_NonConsolidatedMember-574377000JPY
Net income loss (5-year summary)CurrentYTDDuration_NonConsolidatedMember-584510000JPY
Net income loss (5-year summary)Prior1YearDuration_NonConsolidatedMember-759680000JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YTDDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)CurrentYTDDuration_NonConsolidatedMember-JPY
Equity in earnings losses of affiliates if equity method is applied (5-year summary)Prior1YearDuration_NonConsolidatedMember-JPY
Capital stock (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1326051000JPY
Capital stock (5-year summary)CurrentQuarterInstant_NonConsolidatedMember2290271000JPY
Capital stock (5-year summary)Prior1YearInstant_NonConsolidatedMember1467377000JPY
Total number of issued shares (5-year summary)Prior1QuarterInstant_NonConsolidatedMember22159419
Total number of issued shares (5-year summary)CurrentQuarterInstant_NonConsolidatedMember30889419
Total number of issued shares (5-year summary)Prior1YearInstant_NonConsolidatedMember24422619
Net assets (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1081609000JPY
Net assets (5-year summary)CurrentQuarterInstant_NonConsolidatedMember2250917000JPY
Net assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1178338000JPY
Total assets (5-year summary)Prior1QuarterInstant_NonConsolidatedMember1482490000JPY
Total assets (5-year summary)CurrentQuarterInstant_NonConsolidatedMember2640509000JPY
Total assets (5-year summary)Prior1YearInstant_NonConsolidatedMember1543920000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-28.38
Basic earnings loss per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-20.95
Basic earnings loss per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-36.31
Diluted earnings per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-
Diluted earnings per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YTDDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)CurrentYTDDuration_NonConsolidatedMember-
Dividend paid per share (5-year summary)Prior1YearDuration_NonConsolidatedMember-
Equity to asset ratio (5-year summary)Prior1QuarterInstant_NonConsolidatedMember0.713
Equity to asset ratio (5-year summary)CurrentQuarterInstant_NonConsolidatedMember0.844
Equity to asset ratio (5-year summary)Prior1YearInstant_NonConsolidatedMember0.748
Basic earnings loss per share (5-year summary)Prior1QuarterDuration_NonConsolidatedMember-9.80
Basic earnings loss per share (5-year summary)CurrentQuarterDuration_NonConsolidatedMember-7.62
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember30889419
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember31299019
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant30889419
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant31299019
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass